In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Plus Therapeutics (PSTV – Research Report), with a price target of $32.00. The company’s shares opened today at $1.58.
Walsh covers the Healthcare sector, focusing on stocks such as Plus Therapeutics, Theratechnologies, and Actinium Pharmaceuticals. According to TipRanks, Walsh has an average return of -30.8% and a 20.91% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Plus Therapeutics with a $17.33 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $10.95 and a one-year low of $1.24. Currently, Plus Therapeutics has an average volume of 134K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and manufacturing scale up of complex and innovative treatments for patients battling cancer and other life-threatening diseases. The proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. The lead drug product candidate in pipeline, DocePLUS™, is being developed in the U.S. by a dedicated and energetic team of biologists, chemists, engineers, and other professionals. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.
Read More on PSTV:
- Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference
- Biocept, Plus Therapeutics enter licensing agreement for CNSide
- Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay
- Plus Therapeutics expands supply agreement with Biocept
- Plus Therapeutics begins Part B of Phase 1/2a trial for leptomenin metastase
